These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7967431)

  • 1. [Acute hepatotoxicity with intermediate-dose methotrexate in children with leukemia and non-Hodgkin's lymphoma].
    Exadaktylos P; Reiss T; Schobess R; Hommann M; Höhne S; Beck A
    Klin Padiatr; 1994; 206(4):315-8. PubMed ID: 7967431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
    Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
    Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of methotrexate containing chemotherapeutic regimens in the treatment of childhood undifferentiated non-Hodgkin's lymphoma and B cell acute lymphoblastic leukemia.
    Hung IJ; Yang CP
    Taiwan Yi Xue Hui Za Zhi; 1989 Oct; 88(10):1016-22. PubMed ID: 2699490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fulminant hepatic failure induced by intermediate dose methotrexate in a case of non-Hodgkin's lymphoma].
    Kaito K; Katayama T; Yoshida M; Saito A; Kobayashi M; Ochiai S; Masuoka S; Shimada T; Nishiwaki K; Sakai O
    Rinsho Ketsueki; 1990 Nov; 31(11):1862-7. PubMed ID: 2287073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
    Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
    Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
    Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The assessment of hepatic enzymes' levels in children treated for leukemia and non-Hodgkin's lymphomas].
    Nowak K; Trelińska J; Zalewska-Szewczyk B; Stolarska M; Bodalski J
    Wiad Lek; 1998; 51 Suppl 4():129-33. PubMed ID: 10731956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.
    Tiwari P; Thomas MK; Pathania S; Dhawan D; Gupta YK; Vishnubhatla S; Bakhshi S
    Pediatr Hematol Oncol; 2015; 32(8):576-84. PubMed ID: 26558505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
    Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].
    Makhonova LA; Maiakova SA; Kiselev AV; Gordina GA; Balakirev SA; Gavrilova IE; Moiseenko EI; Morozova OV
    Vopr Onkol; 1990; 36(10):1196-200. PubMed ID: 2251813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
    Lange BJ; Blatt J; Sather HN; Meadows AT
    Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [High dosage of Methotrexate in childhood malignancy].
    Moe PJ; Gutteberg TJ
    Tidsskr Nor Laegeforen; 1976 Jun; 96(17-18):997-9. PubMed ID: 1065788
    [No Abstract]   [Full Text] [Related]  

  • 16. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood.
    Weber BL; Tanyer G; Poplack DG; Reaman GH; Feusner JH; Miser JS; Bleyer WA
    NCI Monogr; 1987; (5):207-12. PubMed ID: 3481038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].
    Reiter A; Schrappe M; Yakisan E; Sauter S; Ebell W; Zimmermann M; Hartmann W; Kremens B; Kuhn N; Claviez A
    Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
    Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
    Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.